¼¼°èÀÇ Ã´Ãß »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀå
Spine Biologics
»óǰÄÚµå : 1761077
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 196 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,068,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,204,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ôÃß »ý¹°ÇÐÀû Á¦Á¦ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 29¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 22¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ôÃß »ý¹°ÇÐÀû Á¦Á¦ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 29¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠôÃß ÀÌ½ÄÆíÀº CAGR 3.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 14¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °ñÀÌ½Ä ´ëü¹° ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5¾ï 9,320¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ã´Ãß »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀåÀº 2024³â¿¡ 5¾ï 9,320¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.8%·Î 2030³â±îÁö 5¾ï 9,380¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.5%¿Í 3.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ã´Ãß »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ôÃß »ý¹°ÇÐÀû Á¦Á¦°¡ ôÃß ¼ö¼ú°ú ȸº¹¿¡ º¯È­¸¦ °¡Á®¿À´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ôÃß »ý¹°ÇÐÀû Á¦Á¦´Â »À Àç»ý, À¯ÇÕ °­È­, Á¶Á÷ ȸº¹À» À§ÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ôÃß ¼ö¼ú ¹× ȸº¹¿¡ º¯È­¸¦ °¡Á®¿É´Ï´Ù. °ñÀÌ½ÄÆí, ¼ºÀåÀÎÀÚ, Áٱ⼼Æ÷, ÇÕ¼º »ýüÀç·á¸¦ Æ÷ÇÔÇÑ ÀÌµé »ý¹°ÇÐÀû Á¦Á¦´Â ôÃß °íÁ¤¼ú, Ãß°£ÆÇ ġȯ¼ú, ôÃß º¯Çü ±³Á¤¼ú¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÅðÇ༺ µð½ºÅ©, ôÃßÃø¸¸Áõ, ¿Ü»ó °ü·Ã ¼Õ»ó µî ôÃß ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó À¯Âø·üÀ» °³¼±Çϰí, Ä¡À¯ ½Ã°£À» ´ÜÃàÇϸç, ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­ÇÏ´Â »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ôÃß »ý¹°ÇÐÀû Á¦Á¦´Â ƯÈ÷ ÃÖ¼Òħ½À ôÃß¼ö¼ú(MISS) ¹× º¹ÀâÇÑ Ã´Ãß Àç°Ç¼ú¿¡¼­ ȯÀÚ¿¡°Ô ´õ ³ªÀº ÀÓ»óÀû °á°ú¿Í ºü¸¥ ȸº¹À» °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº ôÃß »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

»ýüÀç·á, ÇÕ¼º°ñÀÌ½ÄÆí, ¼¼Æ÷ ±â¹Ý Ä¡·á¹ýÀÇ ±â¼ú ¹ßÀüÀº ôÃß »ý¹°ÇÐÀû Á¦Á¦ÀÇ À¯È¿¼º, ¾ÈÀü¼º, Àû¿ë ¹üÀ§¸¦ Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Żȸ°ñ ¸ÅÆ®¸¯½º(DBM), À¯ÀüÀÚÀçÁ¶ÇÕ Àΰ£¼ºÀåÀÎÀÚ, µ¿Á¾ À̽İñ Á¦Ç° µî Â÷¼¼´ë »ý¹°ÇÐÀû Á¦Á¦ÀÇ °³¹ßÀº ôÃß °íÁ¤ ¹× »À Ä¡À¯¿¡ º¸´Ù È¿°úÀûÀÎ ¿É¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á¹ý, À¯ÀüÀÚ Ä¡·á, Àç»ýÀÇ·áÀÇ Çõ½ÅÀº Á¶Á÷ º¹±¸, ½Å°æ Àç»ý, ¸ÂÃãÇü ôÃß Ä¡·á¿¡ »õ·Î¿î °¡´É¼ºÀ» Á¦°øÇÏ¸ç °ßÀηÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©·¯ »ý¹°ÇÐÀû Á¦Á¦¿Í ÇÕ¼º ¹°ÁúÀ» ÅëÇÕÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Á¶ÇÕ°ú ÇÏÀ̺긮µå ¼Ö·ç¼ÇÀÇ ÃâÇöÀº ôÃß ¿Ü°ú Àǻ簡 ÀÌ¿ëÇÒ ¼ö ÀÖ´Â Ä¡·á ¿É¼ÇÀ» ³ÐÇôÁÖ¸ç ôÃß »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ôÃß »ý¹°ÇÐÀû Á¦Á¦ »ê¾÷ÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â ½ÃÀå ¼¼ºÐÈ­´Â?

Á¦Ç° À¯Çü¿¡´Â °ñÀ̽ÄÀç, °ñÀ̽ÄÀç ´ëü¹°, Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP), °ñÇü¼º ´Ü¹éÁú(BMP), ¼¼Æ÷ ±â¹Ý ¸ÅÆ®¸¯½º µîÀÌ ÀÖÀ¸¸ç, °ñÀ̽ÄÀç ´ëü¹°Àº ôÃß °íÁ¤¼ú¿¡ ³Î¸® »ç¿ëµÇ¾î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ôÃß »ý¹°ÇÐÀû Á¦Á¦ÀÇ ¿ëµµ´Â ôÃß °íÁ¤¼ú, Ãß°£ÆÇ ġȯ¼ú, ¿Ü»ó º¹±¸¼ú, º¯Çü ±³Á¤¼ú µî ´Ù¾çÇÏÁö¸¸, ôÃß °íÁ¤¼úÀº °íÁ¤·üÀ» ³ôÀÌ°í »ÀÀÇ Ä¡À¯¸¦ ÃËÁøÇÏ´Â »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô±â ¶§¹®¿¡ Áö¹èÀûÀÎ ºÐ¾ß·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ë ºÐ¾ß¿¡´Â º´¿ø, Àü¹® Ŭ¸®´Ð, ¿¬±¸±â°üÀÌ Æ÷ÇԵǸç, º´¿øÀº °íµµÀÇ ¼ö¼ú ´É·Â°ú ´ÙÇÐÁ¦Àû Ä¡·áÆÀÀ¸·Î ÀÎÇØ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Áö¸®ÀûÀ¸·Î ºÏ¹Ì¿Í À¯·´Àº Àç»ýÀÇ·á¿Í ÷´Ü »ý¹°ÇÐÀû Á¦Á¦ÀÇ ³ôÀº äÅ÷ü¿¡ ÈûÀÔ¾î ôÃß »ý¹°ÇÐÀû Á¦Á¦ÀÇ °¡Àå Å« ½ÃÀåÀ̸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ÅõÀÚ Áõ°¡¿Í ôÃß ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ôÃß »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº?

ôÃß »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀåÀÇ ¼ºÀåÀº ÃÖ¼Òħ½À ôÃß ¼ö¼ú(MISS)¿¡¼­ »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, »ýüÀç·á, ÇÕ¼º°ñÀÌ½ÄÆí, Àç»ýÀÇ·áÀÇ ±â¼ú ¹ßÀü, À¯ÇÕ·ü, »À Àç»ý, Ä¡À¯ ½Ã°£ Çâ»ó¿¡ ´ëÇÑ °ü½É Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Ã´Ãß Áúȯ¿¡ ´ëÇØ È¿°úÀûÀÌ°í ¾ÈÀüÇÏ¸ç ¸ÂÃãÈ­µÈ »ý¹°ÇÐÀû Á¦Á¦¸¦ Á¦°øÇØ¾ß ÇÒ Çʿ伺ÀÌ ´Ù¾çÇÑ ¿Ü°úÀû ¹× ºñ¿Ü°úÀû ȯ°æ¿¡¼­ ôÃß »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë »ý¹°ÇÐÀû Á¦Á¦, Áٱ⼼Æ÷ Ä¡·á, À¯ÀüÀÚ Ä¡·á, »ý¹°ÇÐÀû Á¦Á¦ º´¿ëÀÇ ±â¼ú Çõ½ÅÀº Àç»ýÀÇ·á, ÇÕ¼º »ýüÀç·á, ¸ÂÃãÇü ôÃß Ä¡·áÀÇ ¹ßÀü°ú ÇÔ²² ôÃß »ý¹°ÇÐÀû Á¦Á¦ÀÇ À¯È¿¼º, ¾ÈÀü¼º, ½ÃÀ强À» ³ô¿© ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿Ü»ó, Ãß°£ÆÇ º¯¼ºÁõ, ôÃßÃø¸¸Áõ Ä¡·á, ôÃß º¯Çü ±³Á¤¿¡¼­ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Àû¿ë È®´ë, ±Ù°Å ±â¹Ý Áø·á, ÀÓ»ó °¡À̵å¶óÀÎ, ȯÀÚ ±³À°¿¡ ´ëÇÑ Á߿伺 Áõ°¡´Â ½ÃÀå °ü°èÀڵ鿡°Ô »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´Ù¾çÇÑ È¯ÀÚ±ºÀ» À§ÇÑ ºñ¿ë È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ ÇÏÀ̺긮µå ôÃß »ý¹°ÇÐÀû Á¦Á¦ °³¹ß¿¡ ÁýÁßÇϰí ÀÖ´Â °ÍÀÌ Ã´Ãß »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(ôÃß ÀÌ½ÄÆí, °ñÀÌ½Ä ´ëü¹°, ¼¼Æ÷ ±â¹Ý ¸ÅÆ®¸¯½º), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASCs),±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 46°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Spine Biologics Market to Reach US$2.9 Billion by 2030

The global market for Spine Biologics estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Spinal Allografts, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Bone Graft Substitutes segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$593.2 Million While China is Forecast to Grow at 6.8% CAGR

The Spine Biologics market in the U.S. is estimated at US$593.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$593.8 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Spine Biologics Market - Key Trends and Drivers Summarized

Why Are Spine Biologics Transforming Spine Surgery and Recovery?

Spine biologics are transforming spine surgery and recovery by offering innovative solutions for bone regeneration, fusion enhancement, and tissue repair. These biologics, which include bone grafts, growth factors, stem cells, and synthetic biomaterials, are widely used in spinal fusion procedures, disc replacement, and spinal deformity correction. With the increasing prevalence of spinal disorders such as degenerative disc disease, scoliosis, and trauma-related injuries, the demand for biologics that improve fusion rates, reduce healing times, and minimize complications is growing rapidly. Spine biologics are particularly advantageous in minimally invasive spine surgery (MISS) and complex spinal reconstructions, providing better clinical outcomes and faster recovery for patients.

How Are Technological Advancements Impacting the Spine Biologics Market?

Technological advancements in biomaterials, synthetic bone grafts, and cell-based therapies are significantly enhancing the effectiveness, safety, and application scope of spine biologics. The development of next-generation biologics, such as demineralized bone matrices (DBMs), recombinant human growth factors, and allograft bone products, is providing more effective options for spinal fusion and bone healing. Innovations in stem cell-based therapies, gene therapy, and regenerative medicine are gaining traction, offering new possibilities for tissue repair, nerve regeneration, and personalized spine care. Additionally, the emergence of combination biologics and hybrid solutions, which integrate multiple biologic agents and synthetic materials, is expanding the treatment options available for spine surgeons, supporting the growth of the spine biologics market.

Which Market Segments Are Leading the Growth of the Spine Biologics Industry?

Product types include bone grafts, bone graft substitutes, platelet-rich plasma (PRP), bone morphogenetic proteins (BMPs), and cell-based matrices, with bone graft substitutes holding the largest market share due to their widespread use in spinal fusion procedures. Applications of spine biologics span spinal fusion, disc replacement, trauma repair, and deformity correction, with spinal fusion being the dominant segment due to the high demand for biologics that enhance fusion rates and promote bone healing. End-use sectors include hospitals, specialized clinics, and research institutes, with hospitals leading the market due to their advanced surgical capabilities and multidisciplinary care teams. Geographically, North America and Europe are the largest markets for spine biologics, driven by high adoption of regenerative medicine and advanced biologic products, while Asia-Pacific is expected to witness rapid growth due to rising healthcare investments and increasing prevalence of spinal disorders.

What Are the Key Drivers of Growth in the Spine Biologics Market?

The growth in the spine biologics market is driven by several factors, including rising demand for biologics in minimally invasive spine surgery (MISS), technological advancements in biomaterials, synthetic bone grafts, and regenerative medicine, and the increasing focus on enhancing fusion rates, bone regeneration, and healing times. The need to provide effective, safe, and personalized biologics for a wide range of spinal conditions is driving the demand for spine biologics across various surgical and non-surgical settings. Technological innovations in next-generation biologics, stem cell-based therapies, gene therapy, and combination biologics, coupled with advancements in regenerative medicine, synthetic biomaterials, and personalized spine care, are enhancing the efficacy, safety, and marketability of spine biologics, supporting market growth. The expansion of biologic applications in trauma, degenerative disc disease, scoliosis treatment, and spinal deformity correction, along with the growing emphasis on evidence-based practice, clinical guidelines, and patient education, is creating new opportunities for market players. Additionally, the focus on developing cost-effective, scalable, and hybrid spine biologics for diverse patient populations is further propelling the growth of the spine biologics market.

SCOPE OF STUDY:

The report analyzes the Spine Biologics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix); End-Use (Hospitals, Ambulatory Surgery Centers (ASCs), Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â